RAD101
Radiopharmaceutical
Evidence outlook
Brain Metastases: topline reported 2026-07-22
The sponsor reported topline results on 2026-07-22 (RAD101 Phase 2b meets primary endpoint). The announcement is listed under Regulatory events.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06777433 NCT06777433 · Brain Metastases Registry: NCT06777433 | 2 | Concordance between RAD101 PET/MRI and MRI with macrocyclic gadolinium (1 Week); Concordance between RAD101 PET/MRI and MRI with macrocyclic gadolinium (1 Week); Concordance between RAD101 PET/MRI and MRI with macrocyclic gadolinium (1 Week) 2026-04-23 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Competitive landscape
Other Fatty acid synthase (FASN) drugs
Denifanstat, CMS121. Compare all 3 Fatty acid synthase (FASN) drugs
2 other tracked programmes target this mechanism, 1 of them ahead of this one.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| RAD101: this drug | Phase 2 | Radiopharmaceutical | Fatty acid synthase (FASN) | not yet graded | No reviewed efficacy summary | |
| Denifanstat | Phase 3(overall) | Small molecule | Fatty acid synthase (FASN), FASN | Reliable signal | NCT04906421: Histological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) Without Worsening of Fibrosis (by NASH Clinical Research Network [CRN] Fibrosis Score). (52 Weeks): ITT: TVB-2640 50 mg 42/112 | mITT: TVB-2640 50 mg 42/81 vs ITT: Placebo 9/56 | mITT: Placebo 9/45 NCT03938246: Relative change in liver fat (MRI-PDFF) at week 12 vs placebo (+4.5%): -9.6% with 25 mg (LS mean difference -15.5%; 95% CI -31.3 to -0.23; P=.053) and -28.1% with 50 mg (LS mean difference -28.0%; 95% CI -44.5 to -11.6; P=.001) (FASCINATE-1, Gastroenterology 2021). | |
| CMS121 | Phase 1(overall) | Small molecule | Fatty acid synthase (FASN), Fatty acid synthase (FASN) | Weak signal | Featured results are safety only |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent